BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
BioMarin Pharmaceutical (NasdaqGS:BMRN) announced a major debt financing package to support its pending acquisition of Amicus Therapeutics. The company plans to offer US$850 million in senior unsecured notes alongside new term loan facilities. Proceeds are intended to fund the acquisition and related costs, with the transaction expected to reshape BioMarin's capital structure and rare disease portfolio. BioMarin focuses on therapies for rare genetic conditions, a corner of biopharma where approvals and commercial products can be highly concentrated in a few key assets. By targeting Amicus Therapeutics, BioMarin is looking to combine its existing rare disease franchise with Amicus's approved treatments, creating a broader set of therapies for similar patient populations. For investors, the move highlights how rare disease companies often use acquisitions to add products rather than relying only on internal research. The financing signals a clear intent to close the Amicus deal
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Piper Sandler from $122.00 to $84.00. They now have an "overweight" rating on the stock.MarketBeat
- Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments [Yahoo! Finance]Yahoo! Finance
- Should You Buy BioMarin Pharmaceutical Before Feb. 18? [Yahoo! Finance]Yahoo! Finance
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan FacilityPR Newswire
- BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $80.00 price target on the stock.MarketBeat
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 1/29/26 - Form 8-K
- 1/26/26 - Form 8-K
- 1/22/26 - Form 4
- BMRN's page on the SEC website